Trial Profile
Pilot Study of Neoadjuvant Dual Checkpoint Blockade With Concurrent Radiation in Resectable Soft Tissue Sarcoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase 0
Latest Information Update: 15 Nov 2021
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Soft tissue sarcoma
- Focus Adverse reactions
- 03 Nov 2021 Status changed from recruiting to active, no longer recruiting.
- 31 Aug 2018 Status changed from not yet recruiting to recruiting.
- 01 May 2018 Planned End Date changed from 1 Apr 2025 to 1 Aug 2025.